| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/5000 | Human,Mouse,Rat |
| Aliases | Hrd3; SEL1L1; PRO1063; SEL1-LIKE |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human SEL1L |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于SEL1L抗体的3篇参考文献及其简要摘要：
---
1. **文献名称**：*SEL1L regulates adhesion, proliferation and secretory activity of monocytic cells*
**作者**：Cattaneo M. et al.
**摘要**：研究利用SEL1L抗体通过流式细胞术和免疫印迹分析，发现SEL1L蛋白在单核细胞中的表达与细胞黏附、增殖及细胞因子分泌功能密切相关，提示其在免疫调节中的作用。
---
2. **文献名称**：*SEL1L-HRD1 complex is essential for pancreatic β-cell survival under endoplasmic reticulum stress*
**作者**：Sun S. et al.
**摘要**：通过免疫共沉淀和免疫荧光技术结合SEL1L抗体，揭示了SEL1L-HRD1复合物在维持内质网应激下胰岛β细胞存活中的关键机制，为糖尿病研究提供新靶点。
---
3. **文献名称**：*Downregulation of SEL1L predicts poor prognosis in colorectal cancer patients*
**作者**：Li Y. et al.
**摘要**：该研究使用SEL1L抗体对结直肠癌组织进行免疫组化分析，发现SEL1L低表达与患者预后不良显著相关，表明其作为潜在生物标志物的临床价值。
---
如需获取具体文献，建议通过PubMed或Google Scholar输入标题及作者名进一步检索。
**Background of SEL1L Antibody**
The SEL1L antibody is a crucial tool for studying the SEL1L protein, a key component of the endoplasmic reticulum-associated degradation (ERAD) pathway. SEL1L functions as a scaffold protein, forming a complex with Hrd1 (an E3 ubiquitin ligase) to mediate the recognition, ubiquitination, and subsequent proteasomal degradation of misfolded proteins in the endoplasmic reticulum (ER). This process is vital for maintaining cellular protein homeostasis and mitigating ER stress.
SEL1L antibodies are widely used in techniques like Western blotting (WB), immunohistochemistry (IHC), and immunofluorescence (IF) to detect SEL1L expression levels, localization, and interactions in various biological contexts. Research has linked SEL1L dysregulation to diseases such as cancer, neurodegenerative disorders, and metabolic syndromes, highlighting its potential as a therapeutic or diagnostic biomarker. However, challenges remain in ensuring antibody specificity due to variable isoforms, post-translational modifications, or cross-reactivity with homologous proteins. Validation via knockout controls and species-specific considerations (e.g., human, mouse) are critical.
Overall, SEL1L antibodies advance our understanding of ERAD mechanisms, disease pathogenesis, and cellular stress responses, offering insights for both basic research and clinical applications.
×
